Orforglipron in Japanese Adults With Obesity Disease

Phase 3, randomised, double-blind trial of orforglipron in obesity (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Percent Change From Baseline in Body Weight at 72 weeks and Percentage of Participants Who Achieved With Greater Than or Equal to 5% Body Weight Reduction From Baseline at 72 weeks. Started Jul 2023; status: completed.